The US Food and Drug
Administration has given the tick to
Strensiq (asfotase alfa) as the first
approved treatment for perinatal,
infantile and juvenile-onset
hypophosphatasia (HPP).
Also approved is Yondelis
(trabectedin), a chemotherapy, for
the treatment of specific soft tissue
sarcomas (STS) – liposarcoma and
leiomyosarcoma.The above article was sent to subscribers in Pharmacy Daily's issue from 27 Oct 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Oct 15
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.